About the Company
harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving activity against
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HARP News
Harpoon Therapeutics, Inc. Common Stock (HARP)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Global Cytokine Release Syndrome Management Industry
Global Cytokine Release Syndrome Management Industry is expected to reach US$ 44.6 Billion by 2033, growing at a CAGR of 6.7% ...
Harpoon Therapeutics
Health tech executives shared how their companies are putting innovative ideas into action to address the most pressing needs in healthcare, as part of the Vibe at ViVE by MedCity News. Health ...
Merck & Co., Inc. (MRK)
today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be ...
HRTX Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company ...
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be ...
Merck & Co., Inc. (MRKCL.SN)
today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be ...
Harpoon Therapeutics Inc (5HTA.MU)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Todd Foley's Net Worth
Todd Foley has an estimated net worth of $598 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., iTeos Therapeutics, Inc., TriVascular ...
TG Therapeutics Inc TGTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
OMGA Omega Therapeutics, Inc.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease ...
Harpoon Therapeutics, Inc. Common Stock (HARP)
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
Loading the latest forecasts...